Genmab — Januar 2020
-
-
På sådan en stille dag, tør man spørge om der nogle her som har set på Cellectar Bio. Præsentere ydereligere data, update og analyse af deres ph1 og ph2 med CLR 131. bl.a. i R/R MM den 19. Feb Latterlig lille Mcap på 21 m$ men mangler penge. TA ser også lidt spændende ud. https://investor.cellectar.com/press-releases/detail/233/cellectar-biosciences-to-host-a-clr-131-clinical-data-call
-
lahn...Prøv i biotekchatten.
-
Det er ok lahn. Tænkte blot at du kan gøre det begge steder.
-
Vi er vist strøget gennem 1.500.
-
Daratumumab-Based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients https://www.sciencedirect.com/science/article/pii/S2152265020300070?dgcid=rss_sd_all#!
-
Mechanisms of Resistance to Anti-Cd38 Daratumumab in Multiple Myeloma https://www.mdpi.com/2073-4409/9/1/167/htm
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind